NCT05599048View on ClinicalTrials.gov

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

Hyperpolarized 13C-Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging (MRI)

Imaging procedure

DRUG

13C,15N-Urea

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Sigma-Aldrich

UNKNOWN

lead

Robert Bok, MD, PhD

OTHER